This company has been acquired
Neuphoria Therapeutics (BNOX) Stock Overview
A clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BNOX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Neuphoria Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.25 |
| 52 Week High | US$1.60 |
| 52 Week Low | US$0.18 |
| Beta | 0.27 |
| 1 Month Change | -10.02% |
| 3 Month Change | -60.06% |
| 1 Year Change | -82.18% |
| 3 Year Change | -97.96% |
| 5 Year Change | n/a |
| Change since IPO | -98.28% |
Recent News & Updates
Shareholder Returns
| BNOX | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -3.4% | 3.6% | -0.4% |
| 1Y | -82.2% | 26.9% | 12.7% |
Return vs Industry: BNOX underperformed the US Biotechs industry which returned -1.9% over the past year.
Return vs Market: BNOX underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| BNOX volatility | |
|---|---|
| BNOX Average Weekly Movement | 52.1% |
| Biotechs Industry Average Movement | 11.1% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: BNOX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: BNOX's weekly volatility has increased from 28% to 52% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 16 | Spyros Papapetropoulos | www.neuphoriatx.com |
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7, which is in phase 3 clinical trial for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops BNC101, a monoclonal antibody that has completed phase 1 clinical trial that targets cancer stem cells; and BNC105, which is in phase 2 clinical trial for the treatment of refractory colorectal cancer and phase 1 clinical trial for the treatment of patients with relapsed/refractory chronic lymphocytic leukemia.
Neuphoria Therapeutics Inc. Fundamentals Summary
| BNOX fundamental statistics | |
|---|---|
| Market cap | US$2.99m |
| Earnings (TTM) | -US$10.82m |
| Revenue (TTM) | n/a |
Is BNOX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BNOX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$10.82m |
| Earnings | -US$10.82m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did BNOX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 11:13 |
| End of Day Share Price | 2024/12/23 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Neuphoria Therapeutics Inc. is covered by 7 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tanushree Jain | Bell Potter |
| Esther Lannie Hong | Berenberg |
| Katherine Genis | Edison Investment Research |